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AbstrAct
Objective Primary tumour location is regarded as a 
reliable surrogate of colorectal cancer biology. Sensitivity 
to anti-EGFRs (Epidermal Growth Factor Receptor) of 
metastatic transverse colon cancers (mTCCs) has usually 
been assumed similar to right-sided tumours; however, 
evidence about the clinical behaviour of mTCC is limited. 
Thus, to verify sensitivity of mTCC to anti-EGFRs we 
conducted the present study.
Methods Patients with RAS/BRAF wild-type microsatellite 
stable (MSS) mTCC receiving anti-EGFR monotherapy, or in 
combination with irinotecan if clearly irinotecan-refractory, 
were included. Hypothesising an overall response rate 
(ORR) of 35%, 11 patients, of whom at least 3 were 
responders, were necessary to be able to reject the null 
hypothesis of an ORR of 5%, with α and β errors of 0.05 
and 0.20. PRESSING panel and consensus molecular 
subtypes (CMS) were assessed on tumour samples, 
whereas in-silico data were obtained from TCGA dataset.
Results Among nine eligible patients, four and three 
achieved response and disease stabilisation (ORR 44%). At 
a median follow-up of 23.1 months, median progression-
free survival and overall survival were 7.3 (95% CI 3.9 to 
NA) and 15.0 months (95% CI 10.0 to NA), respectively. A 
MET amplification and an ERBB4 S303F substitution were 
detected in patients with rapid disease progression, while 
others had PRESSING panel-negative tumours with CMS2 
or CMS4 subtypes.
Conclusions RAS/BRAF wild-type MSS mTCCs may 
be sensitive to anti-EGFRs, as confirmed by molecular 
analyses.
IntROduCtIOn
Nowadays, patients with RAS and BRAF wild-
type metastatic colorectal cancer (mCRC) 
are the most appropriate candidates for 
anti-EGFR (Epidermal Growth Factor Recep-
tor)-based treatment.1–3 While right-sidedness 
has a well-established negative prognostic 
impact,4 it may also predict resistance to 
anti-EGFR agents, being a reliable surrogate 
marker of a complex molecular landscape 
of negative predictors of benefit from such 
agents,5 but not from antiangiogenic ones.6 7 
summary box
What is already known about this subject?
 ► Primary tumour sidedness (right vs left) has recently 
entered the therapeutic algorithm for the choice of 
the first-line treatment of metastatic colorectal can-
cer (mCRC).
 ► Tumours originating from the transverse colon are 
rare and even if they have been included among 
right-sided tumours in the vast majority of analyses, 
it is not completely clear if they show more similari-
ties with right-sided or left-sided ones.
 ► Their sensitivity to anti-EGFRs is not elucidated.
What does this study add?
 ► Based on an a priori statistical hypothesis, anti-EGFR 
agents were active in patients with RAS and BRAF 
wild-type, microsatellite stable (MSS) transverse 
mCRC.
 ► Genetic determinants of intrinsic resistance were 
found in patients with rapid disease progression 
while signatures potentially related with sensitiv-
ity to anti-EGFRs (consensus molecular subtype 2 
[CMS2] and CMS4) were found in the others.
 ► Consistent data about CMS distribution were found 
in TCGA.
How might this impact on clinical practice?
 ► RAS and BRAF wild-type MSS metastatic transverse 
colon cancers (mTCCs) seem to differ from tumours 
originating from caecum, ascending colon or he-
patic flexure in terms of primary refractoriness to 
anti-EGFRs.
 ► If these results are confirmed by further validation, 
anti-EGFR-containing regimens may be considered 
among other appropriate first-line options for pa-
tients with mTCC.
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Indeed, based on several retrospective data8 and posthoc 
analyses of pivotal randomised clinical trials,9–12 primary 
tumour sidedness entered the therapeutic algorithm for 
the choice of the first-line treatment: while anti-EGFR-
based treatments are the first choice for left-sided RAS 
and BRAF wild-type tumours, bevacizumab-based chemo-
therapy combinations and in particular with the intensi-
fied FOLFOXIRI regimen13 14 are the preferred options 
for patients with right-sided primary tumours according 
to the most recent international guidelines15 and clinical 
recommendations.16
According to the definition adopted in most clinical 
trials, right-sided and left-sided primary tumours are 
defined as those originating proximally or distally to 
the splenic flexure, based on the different embryolog-
ical origin from the midgut and hindgut, respectively. 
However, increasing molecular evidence suggests that a 
continuum of genetic characteristics and gene expression 
profiles can be described throughout different colorectal 
segments from caecum to extraperitoneal rectum, 
rather than a simplistic dicothomic distinction between 
right-sided and left-sided tumours. In particular, genetic 
markers of primary resistance to anti-EGFRs and gene 
expression profiles probably associated to limited benefit 
from these drugs are increasingly prevalent from the 
rectum to the caecum.17–20
Tumours originating from transverse colon are rare 
and even if they have been included among right-sided 
tumours in the vast majority of analyses, it is not completely 
clear if they show more similarities with right-sided or left-
sided ones, so that patients with transverse colon tumours 
were excluded by the hallmark posthoc analysis of the 
phase III head-to-head CALGB80405 trial.12
Drawing from these considerations, we assessed the 
activity of anti-EGFRs in patients with RAS and BRAF wild-
type microsatellite stable (MSS) metastatic transverse 
colon cancer (mTCC). A prospective statistical hypoth-
esis was planned to verify whether the use of anti-EGFRs 
was supported in this subgroup based on a predefined 
threshold of clinical relevance. In order to unveil the 
molecular determinants of our findings, a panel of resis-
tance mechanisms beyond RAS and BRAF mutations, the 
PRESSING panel,19 and consensus molecular subtypes 
(CMS) were analysed both in tissue samples from treated 
patients and in-silico.
PatIents and MetHOds
Patients’ population
We identified and included patients with chemorefrac-
tory/chemotherapy non-eligible, RAS and BRAF wild-type 
MSS mTCC, defined as originating distally to the hepatic 
flexure and proximally to the splenic flexure, receiving 
anti-EGFRs as monotherapy at four Italian high-volume 
institutions (Fondazione IRCCS Istituto Nazionale 
dei Tumori, Milan; Azienda Ospedaliera-Universitaria 
Pisana, Pisa; Istituto Oncologico Veneto, Padova; Azienda 
Sanitaria Universitaria Integrata di Udine, Udine). The 
combination of anti-EGFRs with irinotecan was allowed 
only in the case of irinotecan-refractory disease (ie, with 
previous disease progression during or within 3 months 
from the last dose of the last irinotecan-containing 
regimen), as previously described.21 Transverse primary 
tumour location was assessed through the revision of 
pathological and/or endoscopic reports. Other main 
inclusion criteria were: at least one measurable lesion 
according to RECIST 1.1 at the time of treatment initia-
tion and at least one radiological assessment by CT scan 
or declaration of clinical progression through the treat-
ment with anti-EGFRFs.
Molecular analyses
Genomic alterations included in the PRESSING panel 
were investigated as previously reported,19 thus exploring 
several uncommon anti-EGFR resistance mechanisms 
beyond RAS and BRAF mutations (ie, HER2 amplifica-
tion/activating mutations; MET amplification; NTRK/
ROS1/ALK/RET rearrangements; PIK3CA exon 20 muta-
tions, PTEN inactivating mutations, AKT1 mutations). 
Microsatellite instability (MSI) status was assessed by 
multiplex PCR as previously described.22
For gene expression analysis, total RNA was extracted 
from formalin-fixed, paraffin embedded primary tumour 
samples (Ambion RecoverAll kit as per manufacturers’ 
instructions). When the primary tumour sample was not 
available, RNA was extracted from metastatic deposits. 
Areas with high tumour content were marked by a trained 
pathologist on H&E slides and macrodissected in five 
unstained slides. RNA concentration was quantified with 
NanoDrop 2000 Spectrophotometer (Thermo Fisher). 
The expression of 38 CMS-subtype specific genes and 
10 housekeeping genes was assessed using the nCounter 
Max Analysis System (NanoString Technologies) and 
total RNA in the region of 100 ng according to previously 
described low-cost protocol.23 Each sample was assigned 
to a CMS subtype using a previously validated single-
sample prediction method.24
tCGa data analysis
We downloaded single nucleotide variants (SNVs) and 
clinical data for colon adenocarcinoma and rectum 
adenocarcinoma from the GDC Legacy Archive.25 
Processed data (log2-ratio) for ERBB2 and MET somatic 
copy number alterations were downloaded from cBio 
Portal.26 27 CMS classification for 320 cases was retrieved 
from Guinney et al.20 CMS for additional 27 cases was 
estimated by CMS classifier.28 Data about fusion genes 
involving ALK/ROS/NTRK were retrieved from Pietran-
tonio et al.22 TCGA samples with positive pressing panel 
were defined as those demonstrating at least one of the 
following events: (1) a non-silent SNVs in PTEN (exons 
3–8) or AKT1, or presence of exon 20 PIK3CA mutations; 
(2) ERBB2 hotspot mutations as reported in the litera-
ture;29 (3) presence of ALK/ROS/NTRK gene fusions; (4) 
more or equal than four copies (log2-ratio≥2) for ERBB2 
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Figure 1 Consort diagram of the study depicting the process of patients’ selection. A total of 401 patients with RAS and 
BRAF wild-type mCRC treated with an anti-EGFR containing regimen were reviewed. After screening for primary tumour 
location, 24 patients with mTCC were identified, of whom 9 received an anti-EGFR as single agent or in combination with 
irinotecan if clearly irinotecan-refractory and were included. mCRC, metastatic colorectal cancer; mTCC, metastatic transverse 
colon cancer.
and MET. Statistical analysis was performed by custom R 
scripts.30
statistical design and analyses
The primary objective of the study was to assess the activity 
of anti-EGFRs in RAS and BRAF wild-type mTCC. Hypoth-
esising an overall response rate (ORR) of 35% according 
to RECIST 1.1, deemed as clinically relevant, 11 patients, 
of whom at least 3 were responders, were needed to be 
able to reject the null hypothesis of an ORR of 5%, with α 
and β errors of 0.05 and 0.20.
Disease control rate (DCR) was defined as the 
percentage of patients achieving complete response (CR), 
partial response (PR) or stable disease (SD) according to 
RECIST 1.1. Progression-free survival (PFS) was defined 
as the time from the beginning of the anti-EGFR treat-
ment to the radiological evidence of disease progression 
or last follow-up. Overall survival (OS) was defined as the 
time from the beginning of anti-EGFR treatment to death 
or last follow-up. PFS and OS analyses were estimated 
according to the Kaplan-Meier method.
Results
study population
The flow of patients’ selection is shown in figure 1. Data 
from 401 patients with RAS and BRAF wild-type mCRC 
treated with an anti-EGFR containing regimen were 
reviewed. Among them, 24 patients with mTCC were 
identified, and 9 of them had received an anti-EGFR as 
single agent or in combination with irinotecan, fulfilling 
criteria of irinotecan-refractoriness. Patients’ character-
istics are reported in table 1. Median age was 54 years 
(range, 34–87 years). Most of the patients were females 
(67%), had an Eastern Cooperative Oncology Group 
(ECOG) Performance Status (PS) of 0 (67%), with 
primary tumour resected (89%) and had received the 
anti-EGFR-based treatment beyond the second line of 
therapy (56%). In particular, five patients (56%) had 
received panitumumab single agent, two patients (22%) 
panitumumab plus irinotecan and two patients (22%) 
cetuximab plus irinotecan.
Clinical outcome of patients with RAS and BRAF wild-type 
mtCC treated with anti-eGFR agents
One CR, three PRs, three SDs and two disease progres-
sions (PD) were reported as best responses to anti-EGFR 
based treatment, with an ORR of 44% (95% CI 19% to 
73%) and a DCR of 78% (95% CI 44% to 95%).
At a median follow-up of 23.1 months, median PFS 
was 7.3 months (95% CI 3.9 to NA) (figure 2, panel A) 
and median OS was 15.0 months (95% CI 10.0 to NA) 
(figure 2, panel B). The treatment history of patients 
with clinical benefit is graphically depicted in online 
supplementary file 1. Median treatment duration was 
 o
n
 27 M
arch 2019 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2019-000489 on 8 M
arch 2019. Downloaded from
 
Open access
4 Cremolini C, et al. ESMO Open 2019;4:e000489. doi:10.1136/esmoopen-2019-000489
Table 1 Patients and disease characteristics
Characteristics 
Study 
population
N=9
N %
Age (years) Median
Range min-max
54
34–87
–
–
Gender Male
Female
3
6
33
67
ECOG PS 0
1
6
3
67
33
Primary tumour 
resection
No
Yes
1
8
11
89
Metastatic sites (N) 1
>1
5
4
56
44
Synchronous mets No
Yes
4
5
44
56
Line of anti-EGFR 
tx (N)
1–2
>2
3
6
33
67
Regimen Panitumumab
Panitumumab plus 
irinotecan
Cetuximab plus 
irinotecan
5
2
2
56
22
22
Mets, metastases; tx, treatment.
Figure 2 Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based 
therapy. mTCC, metastatic transverse colon cancer; OS, overall survival; PFS, progression-free survival.
5.1 months (95% CI 3.3 to 8.8). Reasons for treatment 
discontinuation were disease progression in six patients 
and surgery of residual disease in one patient, while treat-
ment was ongoing at the time of data cut-off (May 2018) 
in two cases.
Molecular make-up of patients with RAS and BRAF wild-type 
mtCC
Primary tumour samples were available for both 
PRESSING panel analysis and CMS subtyping (table 2). 
Regarding the two patients with progressive disease at 
the first CT scan reassessment, in one case MET ampli-
fication by bright-field in situ hybridisation was reported 
and ERBB4 S303F substitution,31 31 reasonably related to 
the activation of alternate pathways other than EGFR, 
was found by next generation sequencing in the other 
case. All other seven patients with clinical benefit from 
anti-EGFRs had PRESSING panel-negative tumours and 
CMS2 or CMS4 subtypes.
tCGa validation analysis
In TCGA, a total of 335 records of RAS and BRAF wild-
type tumours with available information about primary 
anatomical location and PRESSING panel determinants 
were retrieved, including 250, 92 and 13 left, right and 
transverse colorectal primary tumours, respectively. As 
detailed in figure 3A, determinants of resistance to anti-
EGFRs included in the PRESSING panel were found in 25 
(10%) out of 250 left-sided, 7 (8%) out of 92 right-sided 
and 2 (15%) out of 13 transverse colon samples (the latter 
being represented by one PTEN c.389G>A substitution 
and one HER2 amplification, respectively). Finally, a total 
of 173 records of RAS and BRAF wild-type tumours with 
available information about primary anatomical location 
and CMS subtypes were retrieved (figure 3B), including 
123, 43 and 7 left, right and transverse colorectal primary 
tumours. Notably, among seven available transverse colon 
samples, no CMS1 and CMS3 subtypes were detected.
dIsCussIOn
The concept of sidedness has recently entered clinical 
recommendations for the choice of the first-line therapy 
of mCRC based on its value as a surrogate marker of a 
complex landscape of molecular differences between 
cancers originating proximally or distally to the splenic 
flexure with meaningful clinical implications. However, 
recent in-depth analyses showed that this dicothomic 
definition is quite simplistic, being unable to properly 
recapitulate regional variations in tumour biology. To this 
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Table 2 Molecular analyses in individual patients with 
mTCC according to PRESSING panel analysis and CMS 
subtypes, with corresponding outcomes in terms of RECIST 
response and progression-free survival
N° 
patient PRESSING panel*
MSI 
status
CMS 
status ORR
PFS, 
months
#1 Negative
TP53 EX 7 R248Q;
ERBB4 EX 8 S303F
MSS CMS1 PD 3.2
#2 Negative
TP53 EX 7 G244V;
STK11 EX 4 G180E
MSS CMS2 PR 6.1
#3 Negative
TP53 EX 6 
R196STOP;
APC EX 15 
E1353STOP
MSS CMS4 CR 13.0+
#4 Negative
TP53 EX 8 R273H;
ATM EX 12 P604S;
APC EX 15 
Q12894STOP
MSS CMS4 PR 5.1+
#5 Negative
TP53 EX 8 R273H;
KDR EX 26 E1126V
MSS CMS4 SD 11.1
#6 Negative
TP53 EX 10 
R342STOP
MSS CMS2 SD 10.0
#7 Negative
TP53 EX 5 F134L
MSS CMS2 PR 3.9
#8 Positive
MET amplified
No point mutations
MSS CMS4 PD 2.9
#9 Negative
TP53 EX 8 G266R;
CTNNB1 EX 3 S37F
MSS NA SD 7.3
*PRESSING panel results are reported overall (negative vs positive) 
and all mutations detected by NGS are detailed.
CMS, consensus molecular subtypes; CR, complete response ; 
EX, exon; MSI, microsatellite instability; MSS, microsatellite stable; 
NGS, next generation sequencing; ORR, objective response; PFS, 
progression-free survival; PR, partial response; SD, stable disease; 
WT, wild-type.
regard, the CRC classification based on the primary loca-
tion, that is, the specific colon segment where tumours 
arise, seems to provide a more accurate snapshot of the 
underpinning tumour biology. By a clinical perspective, 
these considerations are especially relevant for cancers 
arising in the transverse colon, since they were classified 
as right-sided in most subgroup analyses of randomised 
trials, but their molecular landscape, based on mutation 
clustering, seems closer to left-sided tumours.18 As a prac-
tical implication, assessing the sensitivity of RAS and BRAF 
wild-type mTCCs to anti-EGFR monoclonal antibodies is 
crucial in order to properly build the therapeutic route 
of these patients from the very beginning, given the 
substantial impact of the first-line therapy on the whole 
disease history.
Loree et al18 faced this issue, retrospectively evaluating 
the response to anti-EGFR-containing regimens adminis-
tered in second or further lines to 17 patients affected 
by RAS and BRAF wild-type mTCCs showing an ORR 
according to RECIST V.1.1 of 35%, with an 82% DCR 
and a median PFS of 5.9 months. However, all patients 
had received the targeted agent in combination with at 
least one cytotoxic drug, thus preventing from drawing 
conclusions about the actual benefit derived from anti-
EGFR monoclonal antibodies alone.
In order to prospectively challenge these suggestive 
findings, we included in the present analysis only patients 
treated with an anti-EGFR as monotherapy or in combi-
nation with irinotecan in the case of clear irinotecan-re-
fractoriness. Consistently, we limited our investigation 
to patients with RAS and BRAF wild-type tumours, since 
they are the only potential candidates to anti-EGFRs. 
Moreover, given the reasonable association of micro-
satellite instability with limited benefit from a targeted 
approach against one single pathway,19 32 and the preva-
lence of microsatellite instability in mTCC being similar 
to ascending colon and higher than left-sided segments, 
only patients with RAS and BRAF wild-type MSS tumours 
were included.
In our series, an ORR of 44% with a 78% DCR was 
reported, thus outlining a potential role for anti-EGFR 
agents in the treatment of patients with mTCC. The 
prespecified hypothesis underlying our analysis was 
confirmed, since more than three responses were regis-
tered even if only 9 patients were included instead of 11, 
as initially planned. The main limitation of this study is the 
small sample size, due to the rarity of the transverse loca-
tion and the choice to include only patients with RAS and 
BRAF wild-type tumours where the effect of anti-EGFRs 
was clearly distinguishable without the confounding 
effect of the associated chemotherapy backbone.
Though acknowledging the limitations of our prag-
matic approach, including also the lack of a proper 
control arm and the review of retrospectively collected 
data, and therefore the low level of produced evidence, 
a prospective effort to answer this clinically relevant 
question through a randomised clinical trial focused 
on this rare population (RAS and BRAF wild-type, MSS 
mTCCs) would be hardly feasible. On the other hand, 
the validation of present findings in posthoc analyses of 
randomised trials with available information about the 
precise anatomical location would be highly desirable.
By a molecular perspective, heterogeneous features 
were reported in analysed samples and potential mecha-
nisms of intrinsic resistance to anti-EGFRs were found in 
both cases of rapid disease progression. Also with regard 
to CMS classification, most cases presented potentially 
EGFR-dependent signatures, as confirmed also by the in 
silico validation that took advantage of the small number 
of RAS and BRAF wild-type MSS mTCCs included in the 
TCGA database.
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Figure 3 (A) Bar plot showing the frequency of pressing panel negative and positive in the KRAS and BRAF wt cases of 
COAD and READ TCGA datasets. (B) Bar plot showing the frequency of CMS classes in the KRAS and BRAF wt and pressing 
panel positive cases of COAD and READ TCGA datasets. Numbers of cases are reported on the top of each bar. COAD, colon 
adenocarcinoma; READ, rectum adenocarcinoma.
Besides the identified molecular alterations under-
pinning primary resistance to anti-EGFRs, this could 
be also sustained by RAS mutations not recognised by 
conventional tissue analyses at baseline, that could have 
been detected in circulating tumour DNA through liquid 
biopsies.33
Based on our results, RAS and BRAF wild-type MSS 
mTCCs seem to differ from tumours originating from 
caecum, ascending colon or hepatic flexure in terms of 
primary refractoriness to anti-EGFRs. Therefore, if these 
results are confirmed by further validation, anti-EG-
FR-containing regimens may be considered among other 
appropriate first-line options for patients with mTCC. 
The evaluation of a panel of molecular mechanisms of 
intrinsic resistance in RAS and BRAF wild-type tumours, 
that is, the mentioned PRESSING panel,19 could allow 
performing a negative hyperselection of resistant patients, 
in the absence of positive predictors of benefit from anti-
EGFR agents.
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